New drug duo aims to fight Hard-to-Treat cancers
NCT ID NCT07276373
First seen Dec 11, 2025 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants will take part in this early-stage trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGSan Antonio, Texas, 78229, United States
-
Site 02
RECRUITINGWest Valley City, Utah, 84119, United States
-
Site 03
RECRUITINGLos Angeles, California, 90025, United States
-
Site 04
RECRUITINGGrand Rapids, Michigan, 49546, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nenocorilant (a drug) combined with nivolumab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. The combination could cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.